The role of genetic and epigenetic factors in tumor initiation and progression is well
documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA …

Over the past 25 years, research in cancer therapeutics has largely focused on two distinct
lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous …

Purpose: Throughout their development, tumors are challenged by the immune system, and
they acquire features to evade its surveillance. A systematic view of these traits, which shed …

Autophagy is an indispensable mechanism of the eukaryotic cell, facilitating the removal and
renewal of cellular components and thereby balancing the cell's energy consumption and …

Immune checkpoint inhibitors (ICIs) have demonstrated to be highly efficient in treating solid
tumors; however, many patients have limited benefits in terms of response and survival. This …

Autophagy is a tightly regulated catabolic process that facilitates nutrient recycling from
damaged organelles and other cellular components through lysosomal degradation …

HDAC3 modulation shows promise for breast cancer, including triple-negative cases. Novel
pyrazino-hydrazide-based HDAC3 inhibitors were designed and synthesized. Lead …

Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal …

Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …

Programmed cell-death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway
blockade is a promising therapy for the treatment of advanced cancers, including B-cell …